Adjuvant Paclitaxel and Trustuzumab for node-negative, HER-2 positive breast cancer. NEJM, 2015; 372: 134-141.
Tolaney, S.M., et al.
http://www.nejm.org/doi/full/10.1056/NEJMoa1406281?af=R&rss=currentIssue
No single standard treatment exists for patients with small, node-negative, human epidermal growth factor receptor type 2 (HER2)–positive breast cancers, because most of these patients have been ineligible for the pivotal trials of adjuvant trastuzumab.
